| 摘要 |
The invention relates to 3-, 5-, 7-trisubstituted pyrazolo[4,3-d]pyrimidines represented by the general formula I and pharmaceutically acceptable salts thereof, wherein R3 is an optionally substituted alkyl, cycloalkyl, cycloheteroalkyl, cycloalkyl alkyl, aryl or alkylaryl group; R5 is halogen, —NHNH2, —NHOH, NHCONH2, guanylo (NH—C(NH)NH2) an optionally substituted C1-C6 alkyl, alkenyl, alkynyl, C3-C15 cycloalkyl, Rf(C3-C15 cycloalkyl), heterocyclyl, heteroalkyl, aryl, heteroaryl, arylalkylene, arylalkenylene, arylalkynylene, cycloheteroalkyl, cycloheteroalkyl alkyl, heteroarylalkylene, heteroarylalkenylene, heteroarylalkynylene group, the group —C(O)—Ra, —C(O)NRbRc, —SO3Rd, or —NHC(O)Re, wherein Ra and Rf are an optionally substituted C1-C6 alkyl, alkenyl, or alkynyl group, Rb, Rc, and Rd are independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, alkenyl, or alkynyl group, and Re is a hydroxy, amino, alkoxy, alkylamino, optionally substituted C1-C6 alkyl, alkenyl or alkynyl group; or the group —X—R5′, wherein X is —NH—, —O—, —S— or —N(alkyl)- and R5′ is hydrogen, an optionally substituted C1-C6 alkyl, alkenyl, alkynyl, C3-C15 cycloalkyl, Rf(C3-C15 cycloalkyl), aryl, heterocyclyl, hetero C1-C6 alkyl, arylalkylene, arylalkenylene, arylalkynylene, heteroaryl, cycloheteroalkyl, cycloheteroalkyl alkyl, or heteroarylalkylene, heteroarylalkenylene, heteroarylalkynylene group, the group —C(O)—Ra, —C(O)NRbRc, —SO3Rd, or —NHC(O)Re, wherein Ra, Rb, Rc, Rd, Re and Rf have the above meaning, and R7 is halogen, —NHNH2, NHOH, NHCONH2, guanylo (NH—C(NH)NH2) or the group —X—R7′, wherein X has the above meaning and the meaning of R7′ is as defined for R5′.
|
